Octapharma
-
Octapharma: New Consensus Recommendations on Treatment of Secondary Antibody Deficiency in Patients With Haematological Malignancies
LACHEN, Switzerland: New expert consensus guidelines on the use of immunoglobulin replacement therapy (IgRT) in patients with haematological malignancy and…
Read More » -
Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A
LACHEN, Switzerland: Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated…
Read More » - Health
Octapharma to Demonstrate Ongoing Commitment to Improving the Long-term Health of People With Haemophilia A at the 14th EAHAD Annual Congress
LACHEN, Switzerland: Octapharma announced today a satellite symposium and poster presentation at the 14th annual congress of the European Association…
Read More » - Business
Positive Results From ProDERM Study of octagam® 10% in Patients With Dermatomyositis Meeting the Primary Endpoint Will Be Presented at ACR Convergence 2020
LACHEN, Switzerland: Octapharma announces that the final results from the phase III ProDERM study will be presented at the American…
Read More » - Business
Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients
LACHEN, Switzerland: Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing…
Read More » - World
Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency
LACHEN, Switzerland: Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga® in…
Read More »